Is oral naproxen appropriate for treating eye pain?

Oral Naproxen is NOT Appropriate for Eye Pain

Oral naproxen should not be used for eye pain because topical anti-inflammatory agents are the evidence-based first-line treatment, and systemic NSAIDs like naproxen have no established role in ophthalmologic pain management guidelines.

Why Topical Therapy is Superior

The 2017 Ophthalmology guidelines for managing eye pain specifically recommend topical loteprednol 0.5% as the first-line anti-inflammatory agent for ocular pain, particularly neuropathic corneal pain 1. The guideline emphasizes that topical corticosteroids work by inhibiting cytokines, prostaglandins, and leukotriene synthesis directly at the site of inflammation in the eye.

For patients requiring anti-inflammatory therapy for eye conditions:

• First-line: Topical loteprednol 0.5% (four times daily for 2 weeks, then taper)
• Steroid-sparing alternatives: Topical cyclosporine A 0.05%, tacrolimus 0.03%, or lifitegrast 5%
• Adjunctive: Autologous serum tears (20% AST) for nerve regeneration 1

The Problem with Oral NSAIDs for Eye Pain

While naproxen is FDA-approved and effective for various pain conditions including rheumatoid arthritis, osteoarthritis, acute gout, postoperative pain, and dysmenorrhea 2, there is no evidence supporting its use for eye pain specifically. The drug label makes no mention of ophthalmologic indications 2.

The research evidence confirms naproxen's efficacy for:

• Postoperative pain (NNT 2.7 for 50% pain relief) 3
• Musculoskeletal pain 4, 5
• Migraine headaches 6

However, none of these studies address eye pain, and the mechanism of action—systemic prostaglandin inhibition—is less targeted than topical therapy applied directly to the ocular surface.

When Systemic Therapy IS Indicated for Eye Pain

The ophthalmology guidelines do recommend systemic pharmacotherapy, but specifically for neuropathic corneal pain with central sensitization 1. In these cases, the recommended agents are:

• First-line: Tricyclic antidepressants (nortriptyline 25-100 mg at bedtime)
• Alternative first-line: Carbamazepine 400-1200 mg daily for trigeminal neuralgia-type pain

Notably, oral NSAIDs like naproxen are not mentioned in the systemic treatment algorithm for eye pain 1.

Clinical Pitfalls to Avoid

1. Don't treat eye pain like musculoskeletal pain: The ocular surface requires targeted topical therapy, not systemic NSAIDs
2. Risk of missing serious pathology: Eye pain requires ophthalmologic evaluation to rule out conditions like acute angle-closure glaucoma, corneal ulceration, or uveitis—conditions where naproxen would be inappropriate and potentially harmful by delaying proper treatment
3. Preservative concerns: Even topical NSAIDs can be problematic in patients with severe hyperalgesia due to preservatives like benzalkonium chloride 1

The Bottom Line

Use topical loteprednol 0.5% or other topical anti-inflammatory agents as first-line therapy for eye pain. Reserve systemic medications for neuropathic pain with central sensitization, in which case use nortriptyline or carbamazepine—not naproxen. Oral naproxen has no established role in evidence-based eye pain management and should be avoided in favor of targeted topical therapy that delivers medication directly to the affected tissue with fewer systemic side effects.